{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:23:39Z","timestamp":1792794219196,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06576-w","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:57:33Z","timestamp":1762523853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of ileal bile acid transport inhibitors in children with Alagille syndrome: a meta-analysis"],"prefix":"10.1007","volume":"184","author":[{"given":"Jonathan Rodrigues","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas Martins","family":"Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia Botelho","family":"Libonati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima Maria Thaiz","family":"da Fonte Gomes Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lica Luciana","family":"Nau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"2","key":"6576_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/MPG.0000000000001958","volume":"67","author":"BM Kamath","year":"2018","unstructured":"Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N (2018) Systematic review: the epidemiology, natural history, and burden of Alagille syndrome. J Pediatr Gastroenterol Nutr 67(2):148\u2013156","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"6576_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ejhg.2011.181","volume":"20","author":"PD Turpenny","year":"2012","unstructured":"Turpenny PD, Ellard S (2012) Alagille syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 20(3):251\u2013257","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"6576_CR3","first-page":"101","volume":"87","author":"D Alagille","year":"1975","unstructured":"Alagille D, Estrada A, Gerhardt M et al (1975) Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr 87(1):101\u2013105","journal-title":"J Pediatr"},{"issue":"7","key":"6576_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S2468-1253(24)00089-5","volume":"9","author":"N Ovchinsky","year":"2024","unstructured":"Ovchinsky N, Aumar M, Baker A et al (2024) Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomized, placebo-controlled trial. Lancet Gastroenterol Hepatol 9(7):632\u2013645. https:\/\/doi.org\/10.1016\/S2468-1253(24)00089-5","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"6576_CR5","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1002\/hep4.1945","volume":"6","author":"BL Shneider","year":"2022","unstructured":"Shneider BL, Spino CA, Kamath BM et al (2022) Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome. Hepatol Commun 6(8):1922\u20131933. https:\/\/doi.org\/10.1002\/hep4.1945","journal-title":"Hepatol Commun"},{"issue":"10","key":"6576_CR6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep4.1244","volume":"2","author":"BL Shneider","year":"2018","unstructured":"Shneider BL, Spino C, Kamath BM et al (2018) Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome. Hepatol Commun 2(10):1184\u20131198. https:\/\/doi.org\/10.1002\/hep4.1244","journal-title":"Hepatol Commun"},{"issue":"3","key":"6576_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.abd.2021.06.007","volume":"97","author":"TR Nietsche","year":"2022","unstructured":"Nietsche TR, Dotta G, Barcaui CB, Ferraz MLCG (2022) Cholestatic pruritus: a knowledge update. An Bras Dermatol 97(3):332\u2013337. https:\/\/doi.org\/10.1016\/j.abd.2021.06.007","journal-title":"An Bras Dermatol"},{"issue":"8","key":"6576_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41575-021-00437-7","volume":"18","author":"MM D\u00fcll","year":"2021","unstructured":"D\u00fcll MM, Kremer AE (2021) Treatment of pruritus secondary to liver disease. Nat Rev Gastroenterol Hepatol 18(8):473\u2013485. https:\/\/doi.org\/10.1038\/s41575-021-00437-7","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"6576_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.cld.2020.04.007","volume":"24","author":"TJ Kohut","year":"2020","unstructured":"Kohut TJ, Gilbert MA, Loomes KM (2020) Alagille syndrome: a focused review on clinical features, genetics, and treatment. Clin Liver Dis 24(3):479\u2013494. https:\/\/doi.org\/10.1016\/j.cld.2020.04.007","journal-title":"Clin Liver Dis"},{"key":"6576_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdin.2021.02.004","volume":"3","author":"J Lee","year":"2021","unstructured":"Lee J, Suh H, Jung H, Park M, Ahn J (2021) Association between chronic pruritus, depression, and insomnia: a cross-sectional study. JAAD International 3:54\u201360. https:\/\/doi.org\/10.1016\/j.jdin.2021.02.004","journal-title":"JAAD International"},{"issue":"1","key":"6576_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-024-00722-y","volume":"8","author":"R von Maltzahn","year":"2024","unstructured":"von Maltzahn R, Mayo MJ, Smith HT et al (2024) Relationship between pruritus and sleep in participants with primary biliary cholangitis in the phase 2b glimmer trial. J Patient Rep Outcomes 8(1):60. https:\/\/doi.org\/10.1186\/s41687-024-00722-y","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"6576_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1053\/jhep.2002.33332","volume":"35","author":"KM Emerick","year":"2002","unstructured":"Emerick KM, Whitington PF (2002) Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 35(6):1501\u20131506. https:\/\/doi.org\/10.1053\/jhep.2002.33332","journal-title":"Hepatology"},{"issue":"4","key":"6576_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00007890-199508270-00007","volume":"60","author":"J Cardona","year":"1995","unstructured":"Cardona J, Houssin D, Gauthier F et al (1995) Liver transplantation in children with Alagille syndrome: a study of twelve cases. Transplantation 60(4):339\u2013342. https:\/\/doi.org\/10.1097\/00007890-199508270-00007","journal-title":"Transplantation"},{"issue":"8","key":"6576_CR14","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/liv.14553","volume":"40","author":"BM Kamath","year":"2020","unstructured":"Kamath BM, Stein P, Houwen RHJ, Verkade HJ (2020) Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int 40(8):1812\u20131822. https:\/\/doi.org\/10.1111\/liv.14553","journal-title":"Liver Int"},{"issue":"2","key":"6576_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/MPG.0b013e318297e384","volume":"57","author":"V Kronsten","year":"2013","unstructured":"Kronsten V, Fitzpatrick E, Baker A (2013) Management of cholestatic pruritus in pediatric patients with Alagille syndrome. J Pediatr Gastroenterol Nutr 57(2):149\u2013154. https:\/\/doi.org\/10.1097\/MPG.0b013e318297e384","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"6576_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane handbook for systematic reviews of interventions. Version 6.3. London, UK: Cochrane; 2022. Accessed January 5, 2025. www.training.cochrane.org\/handbook"},{"key":"6576_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"6576_CR18","unstructured":"Lopes J, Libonati NB, Esteves IM, Nau AL. PROSPERO record CRD42024623363. Accessed January 10, 2025. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42024623363"},{"key":"6576_CR19","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ.2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"6576_CR20","unstructured":"Sch\u00fcnemann HJ, Oxman AD, Bro\u017cek J, et al. GRADE handbook for grading quality of evidence and strength of recommendations. GRADE Working Group; 2013. Accessed June 30, 2025. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"6576_CR21","unstructured":"GRADE Working Group. GRADEpro GDT: GRADEpro Guideline Development Tool [computer program]. McMaster University; 2023. Accessed June 30, 2025. https:\/\/gradepro.org"},{"issue":"10311","key":"6576_CR22","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01953-1","volume":"398","author":"E Gonzales","year":"2021","unstructured":"Gonzales E, Hardikar W, Stormon M et al (2021) Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomized phase 2 study. Lancet 398(10311):1581\u20131592. https:\/\/doi.org\/10.1016\/S0140-6736(21)01953-1","journal-title":"Lancet"},{"key":"6576_CR23","doi-asserted-by":"publisher","unstructured":"Sutton H, Sokol RJ, Kamath BM. IBAT inhibitors in pediatric cholestatic liver diseases: transformation on the horizon? Hepatology. Published online 2024;79(1):123\u2013134. https:\/\/doi.org\/10.1002\/hep.32745","DOI":"10.1002\/hep.32745"},{"issue":"24","key":"6576_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247526","volume":"11","author":"HST Muntaha","year":"2022","unstructured":"Muntaha HST, Munir M, Sajid SH, Sarfraz Z, Sarfraz A, Robles-Velasco K, Sarfraz M, Felix M, Cherrez-Ojeda I (2022) Ileal bile acid transporter blockers for cholestatic liver disease in pediatric patients with Alagille syndrome: a systematic review and meta-analysis. J Clin Med 11(24):7526. https:\/\/doi.org\/10.3390\/jcm11247526","journal-title":"J Clin Med"},{"key":"6576_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpeds.2022.09.001","volume":"252","author":"BM Kamath","year":"2023","unstructured":"Kamath BM, Goldstein A, Howard R, Garner W, Vig P, Marden JR, Billmyer E, Anderson A, Kirson N, Jacquemin E, Gonzales E (2023) Maralixibat treatment response in Alagille syndrome is associated with improved health-related quality of life. J Pediatr 252:68-75.e5. https:\/\/doi.org\/10.1016\/j.jpeds.2022.09.001","journal-title":"J Pediatr"},{"issue":"5","key":"6576_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101751","volume":"45","author":"U Baumann","year":"2021","unstructured":"Baumann U, Sturm E, Lacaille F, Gonzal\u00e8s E, Arnell H, Fischler B, J\u00f8rgensen MH, Thompson RJ, Mattsson JP, Ekelund M, Lindstr\u00f6m E, Gillberg PG, Torfg\u00e5rd K, Soni PN (2021) Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study. Clin Res Hepatol Gastroenterol 45(5):101751. https:\/\/doi.org\/10.1016\/j.clinre.2021.101751","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"6576_CR27","unstructured":"Canadian Agency for Drugs and Technologies in Health. Maralixibat (Livmarli): indication: for the treatment of cholestatic pruritus in patients with Alagille syndrome: reimbursement recommendation [Internet]. Ottawa, ON: CADTH; May 2024. Accessed June 16, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK604841\/table\/t04\/"},{"key":"6576_CR28","unstructured":"Canadian Agency for Drugs and Technologies in Health. Odevixibat (Bylvay): CADTH reimbursement review: therapeutic area: progressive familial intrahepatic cholestasis [Internet]. Ottawa, ON: CADTH; May 2024. Accessed June 16, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK604831\/"},{"issue":"2","key":"6576_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clinre.2017.08.007","volume":"42","author":"A Th\u00e9baut","year":"2018","unstructured":"Th\u00e9baut A, Debray D, Gonzales E (2018) An update on the physiopathology and therapeutic management of cholestatic pruritus in children. Clin Res Hepatol Gastroenterol 42(2):103\u2013109. https:\/\/doi.org\/10.1016\/j.clinre.2017.08.007","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9358","key":"6576_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S0140-6736(03)12570-6","volume":"361","author":"G Yosipovitch","year":"2003","unstructured":"Yosipovitch G, Greaves MW, Schmelz M (2003) Itch. Lancet 361(9358):690\u2013694. https:\/\/doi.org\/10.1016\/S0140-6736(03)12570-6","journal-title":"Lancet"},{"issue":"7","key":"6576_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bbadis.2014.02.007","volume":"1842","author":"AE Kremer","year":"2014","unstructured":"Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP (2014) Receptors, cells and circuits involved in pruritus of systemic disorders. Biochim Biophys Acta 1842(7):869\u2013892. https:\/\/doi.org\/10.1016\/j.bbadis.2014.02.007","journal-title":"Biochim Biophys Acta"},{"issue":"7154","key":"6576_CR32","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nature06029","volume":"448","author":"YG Sun","year":"2007","unstructured":"Sun YG, Chen ZF (2007) A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 448(7154):700\u2013703. https:\/\/doi.org\/10.1038\/nature06029","journal-title":"Nature"},{"issue":"5","key":"6576_CR33","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1172\/JCI28553","volume":"116","author":"R Paus","year":"2006","unstructured":"Paus R, Schmelz M, B\u00edr\u00f3 T, Steinhoff M (2006) Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 116(5):1174\u20131186. https:\/\/doi.org\/10.1172\/JCI28553","journal-title":"J Clin Invest"},{"issue":"1","key":"6576_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/82956","volume":"4","author":"M Schmelz","year":"2001","unstructured":"Schmelz M (2001) A neural pathway for itch. Nat Neurosci 4(1):9\u201310. https:\/\/doi.org\/10.1038\/82956","journal-title":"Nat Neurosci"},{"issue":"4","key":"6576_CR35","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.25748","volume":"56","author":"AE Kremer","year":"2012","unstructured":"Kremer AE, van Dijk R, Leckie P et al (2012) Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 56(4):1391\u20131400. https:\/\/doi.org\/10.1002\/hep.25748","journal-title":"Hepatology"},{"issue":"4","key":"6576_CR36","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/MPG.0000000000001044","volume":"62","author":"AE Kremer","year":"2016","unstructured":"Kremer AE, Gonzales E, Schaap FG et al (2016) Serum autotaxin activity correlates with pruritus in pediatric cholestatic disorders. J Pediatr Gastroenterol Nutr 62(4):530\u2013535. https:\/\/doi.org\/10.1097\/MPG.0000000000001044","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"6576_CR37","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","volume":"139","author":"AE Kremer","year":"2010","unstructured":"Kremer AE, Martens JJ, Kulik W et al (2010) Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139(3):1008-1018.e1. https:\/\/doi.org\/10.1053\/j.gastro.2010.05.009","journal-title":"Gastroenterology"},{"issue":"7","key":"6576_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hep4.1522","volume":"4","author":"BM Kamath","year":"2020","unstructured":"Kamath BM, Spino C, McLain R et al (2020) Unraveling the relationship between itching, scratch scales, and biomarkers in children with Alagille syndrome. Hepatol Commun 4(7):1012\u20131018. https:\/\/doi.org\/10.1002\/hep4.1522","journal-title":"Hepatol Commun"},{"issue":"1","key":"6576_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-00830-x","volume":"30","author":"D Sun","year":"2024","unstructured":"Sun D, Xie C, Zhao Y et al (2024) The gut microbiota\u2013bile acid axis in cholestatic liver disease. Mol Med 30(1):104. https:\/\/doi.org\/10.1186\/s10020-024-00830-x","journal-title":"Mol Med"},{"key":"6576_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.01.025","author":"I Nyholm","year":"2025","unstructured":"Nyholm I, Hukkinen M, Lohi J et al (2025) Accumulation of altered serum bile acids predicts liver injury after portoenterostomy in biliary atresia. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.025","journal-title":"J Hepatol"},{"key":"6576_CR41","doi-asserted-by":"publisher","unstructured":"Kamath BM, Ye W, Goodrich NP, Childhood Liver Disease Research Network (ChiLDReN) et al (2020) Outcomes of childhood cholestasis in Alagille syndrome: results of a multicenter observational study. Hepatol Commun 4(3):387\u2013398. https:\/\/doi.org\/10.1002\/hep4.1468","DOI":"10.1002\/hep4.1468"},{"key":"6576_CR42","doi-asserted-by":"publisher","unstructured":"Wang KS, Tiao G, Bass LM, Childhood Liver Disease Research Network (ChiLDReN) et al (2017) Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology 65(5):1645\u20131654. https:\/\/doi.org\/10.1002\/hep.29019","DOI":"10.1002\/hep.29019"},{"key":"6576_CR43","unstructured":"Albireo AB. Bylvay summary of product characteristics. G\u00f6teborg, Sweden: Albireo AB; 2024. Accessed April 2, 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bylvay"},{"key":"6576_CR44","unstructured":"Ipsen Biopharmaceuticals. Bylvay package insert. Cambridge, MA: Ipsen Biopharmaceuticals, Inc; 2024. Accessed April 2, 2025. https:\/\/www.bylvayhcp.com\/home"},{"key":"6576_CR45","unstructured":"Livmarli, Inc. Alagille syndrome itch. Livmarli.com. Accessed [April 2, 2025]. https:\/\/livmarli.com\/alagille-syndrome-itch\/"},{"issue":"24","key":"6576_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11247526","volume":"11","author":"HS Muntaha","year":"2022","unstructured":"Muntaha HS, Munir M, Sajid SH, Sarfraz Z, Sarfraz A, Robles-Velasco K et al (2022) Ileal bile acid transporter blockers for cholestatic liver disease in pediatric patients with Alagille syndrome: a systematic review and meta-analysis. J Clin Med 11(24):7526. https:\/\/doi.org\/10.3390\/jcm11247526","journal-title":"J Clin Med"},{"key":"6576_CR47","unstructured":"Ipsen. U.S. Food and Drug Administration approves Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients 12 months and older with Alagille syndrome. Press release. Ipsen; June 13, 2023. Accessed June 27, 2025. https:\/\/www.globenewswire.com\/news-release\/2023\/06\/13\/2687536\/0\/en\/U-S-FDA-approves-Bylvay-for-patients-living-with-cholestatic-pruritus-due-to-Alagille-syndrome.html"},{"key":"6576_CR48","unstructured":"Ipsen. European Medicines Agency grants conditional marketing authorization under exceptional circumstances for Kayfanda (odevixibat) for the treatment of cholestatic pruritus in patients 6 months and older with Alagille syndrome. Press release. Ipsen; September 9, 2024. Accessed June 27, 2025. https:\/\/www.ipsen.com\/press-releases\/bylvay-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels-in-patients-with-pfic-and-algs-2982434\/"},{"key":"6576_CR49","unstructured":"Mirum Pharmaceuticals. U.S. Food and Drug Administration approves LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Press release. Business Wire; September 29, 2021. Accessed June 27, 2025. https:\/\/www.businesswire.com\/news\/home\/20210929005810\/en\/U.S.-FDA-Approves-LIVMARLI-maralixibat-as-the-First-and-Only-Approved-Medication-for-the-Treatment-of-Cholestatic-Pruritus-in-Patients-with-Alagille-Syndrome-One-Year-of-Age-and-Older"},{"key":"6576_CR50","unstructured":"Mirum Pharmaceuticals. U.S. Food and Drug Administration expands the approved use of LIVMARLI (maralixibat) to include treatment of cholestatic pruritus in patients with Alagille syndrome aged 3 months and older. Press release. Drugs.com; March 13, 2024. Accessed June 27, 2025. https:\/\/www.drugs.com\/newdrugs\/mirum-s-livmarli-now-fda-approved-tablet-formulation-6500.html"},{"key":"6576_CR51","unstructured":"Mirum Pharmaceuticals. European Commission approves LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients with Alagille syndrome two months of age and older. Press release. Business Wire; December 13, 2022. Accessed June 27, 2025. https:\/\/www.businesswire.com\/news\/home\/20221213005467\/en\/Mirum-Pharmaceuticals-LIVMARLI-maralixibat-Approved-by-the-European-Commission-for-the-Treatment-of-Cholestatic-Pruritus-in-Patients-with-Alagille-Syndrome-Two-Months-and-Older"},{"issue":"6","key":"6576_CR52","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1097\/HEP.0000000000000502","volume":"78","author":"RJ Sokol","year":"2023","unstructured":"Sokol RJ, Gonzales EM, Kamath BM et al (2023) Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor. Hepatology 78(6):1698\u20131710. https:\/\/doi.org\/10.1097\/HEP.0000000000000502","journal-title":"Hepatology"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06576-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06576-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06576-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:42:35Z","timestamp":1768459355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06576-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6576"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06576-w","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interets"}}],"article-number":"737"}}